Actinogen Medical

Overview
Price performance
Financials
Research
Thematics

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb/III XanaMIA trial will be key for validating the encouraging Xanamem AD data shown to date.

Latest Insights

Healthcare |
Update

15.10.24

Actinogen Medical — A$11.1m capital raise completed

Healthcare |
Update

07.10.24

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Healthcare |
Flash note

27.08.24

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare |
Update

22.08.24

Actinogen Medical — XanaCIDD data narrow the focus in depression

Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Dr Steven Gourlay

CEO and MD
Michael Roberts

Head of investor relations

Balance Sheet

Forecast net cash (A$m)

11.3

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(7.4)	(3.8)	1.4
Relative	(8.2)	(8.7)	(14.7)
52 week high/low	A$0.1/A$0.0

Financials

Actinogen’s Xanamem is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood-brain barrier and target excess brain cortisol, which has been associated with cognitive impairment in chronic brain conditions such as Alzheimer’s disease (AD). Positive results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive (pTau-181) patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity using the validated CDR-SB scale. Actinogen’s Phase IIb/III XanaMIA trial in patients with biomarker-confirmed early AD is underway, and it plans to report interim data in mid CY25. Given the completion of the A$11.1m capital raising announced in September, Actinogen expects to be fully funded through this trial’s completion in mid CY26. It is also evaluating Xanamem as a treatment for depression symptoms in major depressive disorder, following positive efficacy signals shown in the Phase IIa XanaCIDD study.